Plain-English translation of NCT06179160 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called for people with advanced cancer that has spread and carries a specific genetic change (KRAS G12D mutation). Researchers want to find the right dose of this medication and see if it works well either on its own or combined with other cancer treatments. The main goal right now is to understand how safe the medication is and how well patients tolerate it.
Many people with this type of cancer don't have good treatment options, or their cancer stops responding to standard therapies. This medication targets the specific genetic mutation that drives these cancers, offering hope for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly for check-ups, blood tests, and imaging scans to monitor how you're responding to the medication and any side effects. Depending on which part of the trial you join, you may take the medication alone or in combination with other cancer drugs at doses that the researchers gradually increase to find the safest and most effective level. The trial involves multiple visits and ongoing monitoring, but the exact schedule will depend on which group you're assigned to.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States